Evidence map›Paper›PMID 40774597›Full record

ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2025

APPRAISE: A Tool for Appraising Potential for Bias in Real-World Evidence Studies on Medication Effectiveness or Safety.

Katsiaryna Bykov, Ashley Jaksa, Jennifer L Lund, Jessica M Franklin, Cynthia J Girman, Madlen Gazarian, Hongbo Yuan, Stephen Duffield, Seamus Kent, Elisabetta Patorno

Abstract read
In one paragraph

Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katsiaryna BykovDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: kbykov@bwh.harvard.edu.
Ashley JaksaAetion, Inc, Boston, MA, USA.
Jennifer L LundDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jessica M FranklinOptum Epidemiology, Boston, MA, USA.
Cynthia J GirmanCERobs Consulting, Mills River, NC, USA.
Madlen GazarianSchool of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
Hongbo YuanCanada's Drug Agency, Ottawa, Canada.
Stephen DuffieldNational Institute for Health and Care Excellence, Manchester, England, UK.
Seamus KentErasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands.
Elisabetta PatornoDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Funding

Novel approaches to improve comparative effectiveness research of medical and surgical weight reduction strategies in clinical practiceR01DK138036 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Elisabetta Patorno · 2024 to 2026
$2.3M
Applying causal inference methods to improve estimation of the real-world benefits and harms of lung cancer screening - NCI Diversity SupplementR01CA277756 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Louise Henderson, Jennifer Lund · 2023 to 2026
$1.5M
Novel approaches to identify and quantify the impact of drug-drug interactions in older adults with diabetes, with a focus on multimorbidity and polypharmacyK01AG068365 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BYKOV, KATSIARYNA · 2021 to 2025
$621k
Improving the prediction of life expectancy among older adults with advanced cancer using geriatric assessmentR21AG068965 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LUND, JENNIFER · 2021 to 2022
$433k
AHRQ HHS R01 HS027623FDA HHS U01 FD007213NCI NIH HHS R01 CA277756NIA NIH HHS K01 AG068365NIA NIH HHS R21 AG068965NIDDK NIH HHS R01 DK138036
6 · The paper itself

Abstract

objectivesReal-world evidence (RWE) plays an increasingly important role in health technology assessment (HTA), as well as regulatory and clinical decision making. RWE studies, however, are subject to multiple sources of bias, which are often not easy to identify, impeding credibility and inclusion of RWE in decision making. A comprehensive, fit-for-purpose, and easy-to-use bias assessment tool would help streamline RWE evaluation, enabling efficient utilization of RWE for decision making globally.

methodsA working group of the International Society for Pharmacoepidemiology collaborated with HTA experts to develop a tool that could guide bias assessment in observational studies on the comparative safety and effectiveness of medications, building upon existing methodological tools, best practice guidelines, and checklists for the analysis of real-world data. The tool was further tested and refined in collaboration with HTA agencies.

resultsAPPRAISE (APpraisal of Potential for Bias in ReAl-World EvIdence StudiEs) covers key domains through which bias might be introduced into an RWE study: inappropriate study design and analysis, exposure and outcome misclassification, and confounding. Each domain contains a series of questions. Responses to questions autopopulate a summary of the potential for bias within each domain and of the actions to take to avoid, mitigate, or explore the impact of bias.

conclusionsAPPRAISE is a tool to guide bias assessment in observational studies on medication comparative effectiveness or safety. Although the tool was designed for HTA, it will be useful for many other users of RWE and will help guide optimized RWE generation.

Indexed as

Technology Assessment, BiomedicalBiasEvidence-Based MedicineHumansObservational Studies as TopicPharmacoepidemiologyResearch DesignassessmentbiasRWEvalidity

Identifiers

PMID40774597
PMCPMC12392756

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.